OKC pharmaceutical firm acquired in deal valued up to $665 million
By Don Mecoy
Copyright © 2016, The Oklahoma Publishing Company
Some Oklahoma angel investors are getting their wings.
Those “angels,” a term for individual investors in early stage companies, will get payoffs ranging from about five times to about 20 times what they risked in the development of Oklahoma City-based Selexys Pharmaceuticals Corp.
Selexys has closed a deal to sell the company for up to $665 million to global drug giant Novartis.
Former Selexys CEO Scott Rollins said all the early investments in the company came from Oklahomans and state-based entities.
“It’s been a great story,” Rollins said Monday. “They’re all going to make a lot of money.”